| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Research and development | 1,143 | |||
| General and administrative | 151,451 | |||
| Total operating expenses | 152,594 | |||
| Loss from operations | -152,594 | |||
| Net loss and comprehensive loss | -152,594 | |||
| Earnings per share, basic | -0.76 | |||
| Earnings per share, diluted | -0.76 | |||
| Weighted average number of shares outstanding, basic | 201,686,617 | |||
| Weighted average number of shares outstanding, diluted | 201,686,617 | |||
Semnur Pharmaceuticals, Inc. (SMNRW)
Semnur Pharmaceuticals, Inc. (SMNRW)